腰椎引流联合鞘内注射尼卡地平治疗动脉瘤性蛛网膜下腔出血
动脉瘤破裂所致蛛网膜下腔出血患者经腰椎引流预防性使用鞘内钙通道拮抗剂
The purpose of this study is to determine the effectiveness of prophylactic administration of intra-thecal nicardipine though lumbar cerebrospinal fluid drain in prevention of symptomatic vasospasm in patients with subarachnoid hemorrhage due to rupture of cerebral aneurysms.
研究概览
详细说明
This is a triple-blinded, prospective, sham, randomized study. The purpose of this research is to determine the effectiveness of prophylactic administration of intra-thecal nicardipine though lumbar cerebrospinal fluid drain in prevention of symptomatic vasospasm in patients with subarachnoid hemorrhage due to rupture of cerebral aneurysms. Patients will be randomized to standard treatment of cerebral vasospasm with prophylactic administration of intrathecal nicardipine vs standard treatment alone. The medication used is FDA approved and will be used through an intra-thecal route through a lumbar drain which is indicated in patients with subarachnoid hemorrhage.
研究类型
注册 (估计的)
阶段
- 第四阶段
联系人和位置
学习联系方式
- 姓名:Sajid Suriya, MD
- 电话号码:847-723-2078
- 邮箱:Sajid.suriya@aah.org
学习地点
-
-
Illinois
-
Park Ridge、Illinois、美国、60068
- Advocate Lutheran General Hospital
-
接触:
- Sajid Suriya, MD
- 电话号码:847-723-2078
- 邮箱:Sajid.suriya@aah.org
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age ≥18 years
- Aneurysmal subarachnoid hemorrhage with Hunt and Hess score 3 or less
- Patient or legal authorized representative available to sign the informed consent form
- Pre-morbid modified Rankin scale of 0 or 1.
- Patients who have lumbar drain placed or planned for cerebrospinal fluid diversion per standard of care
- Patients who are able to be randomized within 72 hours from arrival with aneurysmal subarachnoid hemorrhage or within 24 hours from lumbar drain placement
Exclusion Criteria:
- Pregnant females
- Subarachnoid hemorrhage (SAH) with hunt and hess scale of >3
- SAH due to etiology other than aneurysmal rupture
- Any contraindications in patients receiving calcium channel antagonists like hypersensitivity to dihydropyridines
- Active central nerve infection (CNS) infection or high suspicion of CNS infection
- Hemodynamic instability preventing the use of Nicardipine
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
假比较器:Standard of Care
standard treatment of cerebral vasospasm and sham injection of 10 mL preservative-free normal saline in luer-lock sterile syringe |
10 mL preservative-free normal saline in luer-lock sterile syringe every 24 hours from randomization through day 14 post-bleed or lumbar drain removal, whichever occurs first. |
|
实验性的:Standard of Care Plus Nicardipine
standard treatment of cerebral vasospasm with prophylactic administration of intrathecal nicardipine |
Nicardipine 4 mg will be diluted in preservative-free normal saline to 10 mL in luer-lock sterile syringe every 24 hours from randomization through day 14 post-bleed or lumbar drain removal, whichever occurs first. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of Vasospasm
大体时间:up to hospitalization day 21
|
The incidence of symptomatic clinical or radiographic vasospasm in patients treated with prophylactic administration of intrathecal nicardipine though lumbar drain |
up to hospitalization day 21
|
|
Incidence of Delayed Cerebral Ischemia
大体时间:up to hospitalization day 21
|
The incidence of symptomatic clinical or radiographic delayed cerebral ischemia in patients treated with prophylactic administration of intrathecal nicardipine though lumbar drain |
up to hospitalization day 21
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Modified Rankin Scale Score
大体时间:month 6
|
The Modified Rankin Scale is a clinical tool used to assess the functional disability after a stroke. It is a six-point ordinal scale that measures the patient's ability to perform activities of daily living. Score Range: 0 no symptoms, 1 no significant disability, 2 slight disability, 3 moderate disability, 4 moderately severe disability, 5 severe disability, 6 dead. |
month 6
|
|
Incidence of Meningitis
大体时间:up to hospitalization day 21
|
Incidence of meningitis as confirmed by clinical and laboratory findings |
up to hospitalization day 21
|
合作者和调查者
调查人员
- 首席研究员:Krishna Joshi, MD、Advocate Lutheran General Hospital
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.